Nicole Casasanta, MD
@ncasasanta.bsky.social
Heme/Onc Fellow @YaleCancer | Aspiring Breast Oncologist interested in clinical/translational research
📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
June 2, 2025 at 4:52 PM
📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
June 2, 2025 at 1:16 PM
🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
June 2, 2025 at 12:03 PM
🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔹Imbalance between lines of therapy makes interpretation challenging
June 1, 2025 at 8:37 PM
🔹Imbalance between lines of therapy makes interpretation challenging
Looking forward to joining the research community investigating ADCs!✨ @yalecancer.bsky.social
June 1, 2025 at 12:27 AM
Looking forward to joining the research community investigating ADCs!✨ @yalecancer.bsky.social
May 31, 2025 at 3:28 PM